FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311563040> ?p ?o ?g. }

• W4311563040 abstract "Abstract Background Omadacycline (OMC) is a novel tetracycline class (aminomethylcycline) antibacterial FDA approved for treatment of acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by indicated organisms. OMC is active against bacterial isolates expressing resistance to tetracycline, penicillin, fluoroquinolones, macrolides, and vancomycin. This study has been funded in whole or in part by Federal funds from the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Assistant Secretary for Preparedness and Response, under Contract No. 75A50120C00001. Methods 14,000 bacterial clinical isolates were collected from 31 medical centers in the USA (2020-2021) in the SENTRY Surveillance Program. Isolates were collected from the following infection types: bloodstream (24.1%), pneumonia in hospitalized patients (22.6%), skin and skin structure (SSSI; 22.4%), urinary tract (15.9%), intraabdominal (5.5%), community acquired respiratory tract (8.3%) and other (1.2%). Identifications were confirmed by MALDI-TOF. Susceptibility testing of OMC and comparators was conducted according to CLSI M07 (2018) and M100 (2022) guidelines. OMC MIC results were interpreted using FDA breakpoints (BPs). Results OMC demonstrated potent in vitro activity against S. aureus (MIC90, 0.12 mg/L; 99.0% susceptible [S]) from SSSI, including 98.0% of MRSA (Table). From RTI, 99.6% of MSSA were S. 97.6% of S. lugdunensis and 95.5% of S. anginosus group isolates from SSSI were susceptible to OMC. All S. pyogenes and E. faecalis (including vancomycin-resistant [R]) isolates from SSSI were S to OMC. 99.8% of S. pneumoniae isolates from RTI were S to OMC, as were 100% of penicillin-R and tetracycline-R strains. H. influenzae susceptibility to OMC was 99.8%. Susceptibility of E. cloacae and K. pneumoniae isolates from all infection types to OMC was 88.9% and 90.4%, respectively. Conclusion OMC demonstrated potent in vitro activity against staphylococci, streptococci, E. faecalis, H. influenzae, E. cloacae, and K. pneumoniae isolates, including drug-resistant strains, regardless of infection type. Disclosures Michael D. Huband, BS, AbbVie: Grant/Research Support|Melinta: Grant/Research Support Jennifer M. Streit, BS, MT(ASCP), Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Shionogi: Grant/Research Support Helio S. Sader, MD, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|Melinta: Grant/Research Support|Nabriva Therapeutics: Grant/Research Support|Pfizer: Grant/Research Support Mariana Castanheira, PhD, AbbVie: Grant/Research Support|Cidara: Grant/Research Support|GSK: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support." @default.
• W4311563040 created "2022-12-27" @default.
• W4311563040 creator A5014992940 @default.
• W4311563040 creator A5018102677 @default.
• W4311563040 creator A5040648017 @default.
• W4311563040 creator A5045551151 @default.
• W4311563040 creator A5089371529 @default.
• W4311563040 date "2022-12-01" @default.
• W4311563040 modified "2023-10-17" @default.
• W4311563040 title "2044. <i>In Vitro</i> Activity of Omadacycline Against 14,000 Bacterial Isolates from the United States by Infection Type (2020-2021)" @default.
• W4311563040 doi "https://doi.org/10.1093/ofid/ofac492.1666" @default.
• W4311563040 hasPublicationYear "2022" @default.
• W4311563040 type Work @default.
• W4311563040 citedByCount "0" @default.
• W4311563040 crossrefType "journal-article" @default.
• W4311563040 hasAuthorship W4311563040A5014992940 @default.
• W4311563040 hasAuthorship W4311563040A5018102677 @default.
• W4311563040 hasAuthorship W4311563040A5040648017 @default.
• W4311563040 hasAuthorship W4311563040A5045551151 @default.
• W4311563040 hasAuthorship W4311563040A5089371529 @default.
• W4311563040 hasConcept C126322002 @default.
• W4311563040 hasConcept C174802600 @default.
• W4311563040 hasConcept C2777914695 @default.
• W4311563040 hasConcept C2778980435 @default.
• W4311563040 hasConcept C2779489039 @default.
• W4311563040 hasConcept C2780923616 @default.
• W4311563040 hasConcept C2781414143 @default.
• W4311563040 hasConcept C501593827 @default.
• W4311563040 hasConcept C523546767 @default.
• W4311563040 hasConcept C54355233 @default.
• W4311563040 hasConcept C71924100 @default.
• W4311563040 hasConcept C86803240 @default.
• W4311563040 hasConcept C89423630 @default.
• W4311563040 hasConceptScore W4311563040C126322002 @default.
• W4311563040 hasConceptScore W4311563040C174802600 @default.
• W4311563040 hasConceptScore W4311563040C2777914695 @default.
• W4311563040 hasConceptScore W4311563040C2778980435 @default.
• W4311563040 hasConceptScore W4311563040C2779489039 @default.
• W4311563040 hasConceptScore W4311563040C2780923616 @default.
• W4311563040 hasConceptScore W4311563040C2781414143 @default.
• W4311563040 hasConceptScore W4311563040C501593827 @default.
• W4311563040 hasConceptScore W4311563040C523546767 @default.
• W4311563040 hasConceptScore W4311563040C54355233 @default.
• W4311563040 hasConceptScore W4311563040C71924100 @default.
• W4311563040 hasConceptScore W4311563040C86803240 @default.
• W4311563040 hasConceptScore W4311563040C89423630 @default.
• W4311563040 hasIssue "Supplement_2" @default.
• W4311563040 hasLocation W43115630401 @default.
• W4311563040 hasOpenAccess W4311563040 @default.
• W4311563040 hasPrimaryLocation W43115630401 @default.
• W4311563040 hasRelatedWork W2018382434 @default.
• W4311563040 hasRelatedWork W2037263811 @default.
• W4311563040 hasRelatedWork W2162858412 @default.
• W4311563040 hasRelatedWork W2382345126 @default.
• W4311563040 hasRelatedWork W2410645540 @default.
• W4311563040 hasRelatedWork W2565169118 @default.
• W4311563040 hasRelatedWork W2904416310 @default.
• W4311563040 hasRelatedWork W3195958508 @default.
• W4311563040 hasRelatedWork W93776791 @default.
• W4311563040 hasRelatedWork W3144567525 @default.
• W4311563040 hasVolume "9" @default.
• W4311563040 isParatext "false" @default.
• W4311563040 isRetracted "false" @default.
• W4311563040 workType "article" @default.